News

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

A new survey reveals the significant disconnect between dermocosmetic labeling and clinical reality. Explore more and vote in today's poll.

Weekly microneedling combined with daily topical 5% minoxidil produced statistically significant hair density gains in 40 women with female pattern hair loss.

Aclaris Therapeutics shares promising Phase 1a data for ATI-052, showing long-acting dual Th2 blockade, and advances ATI-2138 toward Phase 2b lichen planus studies.

The application is based on phase 3 UP-AA trial data showing significant hair regrowth in patients with severe alopecia areata.

Even nonadvanced forms of systemic mastocytosis can significantly impact patients’ quality of life, though new treatments are improving outcomes.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

The deal would vault the combined company to 7th-largest biosimilar player globally, with direct implications for biologic access in dermatology.

Part A of Study '302' demonstrated statistically significant and clinically meaningful hair growth in men with androgenetic alopecia, with a favorable safety profile and no cardiac adverse events.

Learn how narcissistic traits and body dysmorphia could shape cosmetic dermatology visits, with red flags, screening tips, and safer patient care.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.

The FDA has accepted the resubmitted BLA for relabotulinumtoxinA, a next-generation neuromodulator for treating facial lines in adults.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the approval of dupilumab for pediatric CSU, phase 2b hair growth results with rezpegaldesleukin, multispecific biologics for AD, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Gain exclusive insights from AAD on rapid-onset topicals, durable biologic control, and a growing emphasis on stringent, patient-centered targets shaping atopic dermatitis care.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of April.

Potential FDA approval of TrenibotE was delayed due to manufacturing-related issues, with no concerns regarding safety, efficacy, or clinical trial data.

Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.

Renal transplant patients face frequent warts, fungal infections, and steroid acne, according to new 10-year data.

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

Although microbes inhabit many body sites, the skin is one of the most densely populated areas after the gastrointestinal tract.

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

Clinicians agreed that itch — not lesion count or BSA alone — is the most clinically meaningful driver of treatment escalation in patients with atopic dermatitis.

New 140-week data show that upadacitinib keeps itch, sleep, and quality-of-life gains steady in patients with moderate to severe atopic dermatitis (AD).

Patients frequently experience persistent symptoms, visible lesions, and recurrent flares that affect daily functioning and self-image.